<SEC-DOCUMENT>0001453687-22-000136.txt : 20221103
<SEC-HEADER>0001453687-22-000136.hdr.sgml : 20221103
<ACCEPTANCE-DATETIME>20221103080023
ACCESSION NUMBER:		0001453687-22-000136
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20221103
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221103
DATE AS OF CHANGE:		20221103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SELECTA BIOSCIENCES INC
		CENTRAL INDEX KEY:			0001453687
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37798
		FILM NUMBER:		221356316

	BUSINESS ADDRESS:	
		STREET 1:		65 GROVE STREET
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		617-923-1400

	MAIL ADDRESS:	
		STREET 1:		65 GROVE STREET
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>selb-20221103.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:4896fb3f-ac14-41b0-9b6b-0207fb0b8dc2,g:e4027e9c-0c95-4fb1-84c4-695c0f8d790e,d:26a2d79e282342c8a9d9cc7850dfc0eb--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>selb-20221103</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl80L2ZyYWc6MDkxOTVkYzg0YjFlNGE3Y2E3M2JjMmI2ZjU1MTAzMTMvdGFibGU6MGUyMTkwOTU0YzBiNDhhZDg0ZmM0Y2VhMDY1ODMxNzUvdGFibGVyYW5nZTowZTIxOTA5NTRjMGI0OGFkODRmYzRjZWEwNjU4MzE3NV8wLTEtMS0xLTY0NTYx_9c8a344e-d9c3-4ce3-9453-bf1873bfe094">0001453687</ix:nonNumeric><ix:nonNumeric contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl80L2ZyYWc6MDkxOTVkYzg0YjFlNGE3Y2E3M2JjMmI2ZjU1MTAzMTMvdGFibGU6MGUyMTkwOTU0YzBiNDhhZDg0ZmM0Y2VhMDY1ODMxNzUvdGFibGVyYW5nZTowZTIxOTA5NTRjMGI0OGFkODRmYzRjZWEwNjU4MzE3NV8xLTEtMS0xLTY0NTYx_9a37ee6f-c57e-4b01-ba31-4a8d5d625aea">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="selb-20221103.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-03</xbrli:startDate><xbrli:endDate>2022-11-03</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i26a2d79e282342c8a9d9cc7850dfc0eb_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGV4dHJlZ2lvbjpkNTA4ZWZmYWMzZjc0YzQ4YTRhMmUwMGQ4ZWQyZmU0Zl8xMjcx_f4528ed7-e0c7-4d5a-b074-0cac8386263d">8-K</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">the Securities Exchange Act of 1934</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGV4dHJlZ2lvbjpkNTA4ZWZmYWMzZjc0YzQ4YTRhMmUwMGQ4ZWQyZmU0Zl8yMzQ_375009c3-57ff-4eec-96d6-be4bd2a8fd75">November 3, 2022</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGV4dHJlZ2lvbjpkNTA4ZWZmYWMzZjc0YzQ4YTRhMmUwMGQ4ZWQyZmU0Zl8xMjY0_028fdc0b-06fc-47ad-b3aa-2c881284d146">SELECTA BIOSCIENCES,&#160;INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:29.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.794%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGFibGU6ZWMxZWRmNmRkZDZhNGJkNmFmMzRhZjkxMzYzNWFhYjMvdGFibGVyYW5nZTplYzFlZGY2ZGRkNmE0YmQ2YWYzNGFmOTEzNjM1YWFiM18wLTAtMS0xLTY0NTYx_0aecd294-e04e-40a4-99e4-7c44601a6da3">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGFibGU6ZWMxZWRmNmRkZDZhNGJkNmFmMzRhZjkxMzYzNWFhYjMvdGFibGVyYW5nZTplYzFlZGY2ZGRkNmE0YmQ2YWYzNGFmOTEzNjM1YWFiM18wLTItMS0xLTY0NTYx_3811281f-ab82-4c71-a151-89b735d47add">001-37798</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGFibGU6ZWMxZWRmNmRkZDZhNGJkNmFmMzRhZjkxMzYzNWFhYjMvdGFibGVyYW5nZTplYzFlZGY2ZGRkNmE0YmQ2YWYzNGFmOTEzNjM1YWFiM18wLTQtMS0xLTY0NTYx_44195484-e640-4b02-90fb-41e04e68bdd2">26-1622110</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction <br/>of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">   </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGV4dHJlZ2lvbjpkNTA4ZWZmYWMzZjc0YzQ4YTRhMmUwMGQ4ZWQyZmU0Zl8xMjcy_35ef3eef-e2ec-425f-8b63-cb2100338d18">65 Grove Street,</ix:nonNumeric> <ix:nonNumeric contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGV4dHJlZ2lvbjpkNTA4ZWZmYWMzZjc0YzQ4YTRhMmUwMGQ4ZWQyZmU0Zl8xMjcz_992f4329-ffe5-40eb-ba57-fd1bdceae609">Watertown,</ix:nonNumeric> <ix:nonNumeric contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGV4dHJlZ2lvbjpkNTA4ZWZmYWMzZjc0YzQ4YTRhMmUwMGQ4ZWQyZmU0Zl8xMjY2_896c4a5b-a4bf-4a5e-900f-1846236fd4f0">MA</ix:nonNumeric> <ix:nonNumeric contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGV4dHJlZ2lvbjpkNTA4ZWZmYWMzZjc0YzQ4YTRhMmUwMGQ4ZWQyZmU0Zl8xMjY1_8a825411-1d3e-4e30-a930-c08ab8bbda74">02472</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)(Zip Code)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGV4dHJlZ2lvbjpkNTA4ZWZmYWMzZjc0YzQ4YTRhMmUwMGQ4ZWQyZmU0Zl8xMjY3_9a97d05c-1e42-4328-9f0b-5f16566c2580">617</ix:nonNumeric>) <ix:nonNumeric contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGV4dHJlZ2lvbjpkNTA4ZWZmYWMzZjc0YzQ4YTRhMmUwMGQ4ZWQyZmU0Zl8xMjY4_e53392cd-4165-4249-811f-b7e93a8024a3">923-1400</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.334%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGFibGU6NWRkMjgyNDIzNGYxNGZhYzg4NjFiMjgwMmYzYTM0MmYvdGFibGVyYW5nZTo1ZGQyODI0MjM0ZjE0ZmFjODg2MWIyODAyZjNhMzQyZl8wLTAtMS0xLTY0NTYx_c7191237-cbbb-4051-8bd6-6bf293c0d886">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGFibGU6NWRkMjgyNDIzNGYxNGZhYzg4NjFiMjgwMmYzYTM0MmYvdGFibGVyYW5nZTo1ZGQyODI0MjM0ZjE0ZmFjODg2MWIyODAyZjNhMzQyZl8yLTAtMS0xLTY0NTYx_9956eab2-491e-45ec-8c0e-9ba02818e14e">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGFibGU6NWRkMjgyNDIzNGYxNGZhYzg4NjFiMjgwMmYzYTM0MmYvdGFibGVyYW5nZTo1ZGQyODI0MjM0ZjE0ZmFjODg2MWIyODAyZjNhMzQyZl80LTAtMS0xLTY0NTYx_c08b8ce5-ca44-4273-bb6a-1c41fe20f44c">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGFibGU6NWRkMjgyNDIzNGYxNGZhYzg4NjFiMjgwMmYzYTM0MmYvdGFibGVyYW5nZTo1ZGQyODI0MjM0ZjE0ZmFjODg2MWIyODAyZjNhMzQyZl82LTAtMS0xLTY0NTYx_7f96fa20-4517-4720-932a-6741ee7ef8c4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:39.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.517%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGFibGU6M2Q5MjdiODI4ZGM3NDE1NWJhZjRkNzJkZWE0ZWVmYjQvdGFibGVyYW5nZTozZDkyN2I4MjhkYzc0MTU1YmFmNGQ3MmRlYTRlZWZiNF8zLTAtMS0xLTY0NTYx_144930e1-78ba-435a-bdc1-cf26cad7643e">Common Stock (Par Value $0.0001)</ix:nonNumeric></span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGFibGU6M2Q5MjdiODI4ZGM3NDE1NWJhZjRkNzJkZWE0ZWVmYjQvdGFibGVyYW5nZTozZDkyN2I4MjhkYzc0MTU1YmFmNGQ3MmRlYTRlZWZiNF8zLTEtMS0xLTY0NTYx_bba0c4dd-c2bf-4e79-a61a-0d8220625d07">SELB</ix:nonNumeric></span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGFibGU6M2Q5MjdiODI4ZGM3NDE1NWJhZjRkNzJkZWE0ZWVmYjQvdGFibGVyYW5nZTozZDkyN2I4MjhkYzc0MTU1YmFmNGQ3MmRlYTRlZWZiNF8zLTItMS0xLTY0NTYx_ede2d859-5747-474e-bb8b-f0466dfd8136">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGV4dHJlZ2lvbjpkNTA4ZWZmYWMzZjc0YzQ4YTRhMmUwMGQ4ZWQyZmU0Zl8xMjY5_985c8629-68bc-45d4-a613-e0881b520a2d">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:7pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.780%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i26a2d79e282342c8a9d9cc7850dfc0eb_7"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02. Results of Operations and Financial Condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 3, 2022, Selecta Biosciences, Inc. announced its financial results for the quarter ended September 30, 2022. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained in Item 2.02 of this Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01. Financial Statements and Exhibits.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;Exhibits</span></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.088%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit991_earningsrelease.htm">99.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit991_earningsrelease.htm">Press Release issued on November 3, 2022</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i26a2d79e282342c8a9d9cc7850dfc0eb_10"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:47.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SELECTA BIOSCIENCES,&#160;INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November 3, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Carsten Brunn, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carsten Brunn, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit991_earningsrelease.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ie3d03faf11e94bd68e0dcff3bcf9ff56_1"></div><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div><img alt="selectalogoa06.jpg" src="selectalogoa06.jpg" style="height:74px;margin-bottom:5pt;vertical-align:text-bottom;width:204px"></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Selecta Biosciences Reports Third Quarter 2022 Financial Results </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">and Provides Business Update</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">&#8212; DISSOLVE I &#38; II studies of SEL-212 in Chronic Refractory Gout remain on track for joint topline data readout in Q1 2023 &#8212; </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">&#8212; SEL-302, Selecta&#8217;s wholly owned gene therapy in combination with ImmTOR for the treatment of Methylmalonic Acidemia (MMA), remains on track to begin a Phase 1 trial in Q4 2022 &#8212; </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">&#8212; As of September 30, 2022, Selecta had approximately $148.0 million in cash, cash equivalents, restricted cash and marketable securities, which is expected to provide runway into mid-2024 &#8212; </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">&#8212; Candidate selection for an IL-2 and IgA protease expected by year end 2022 &#8212;   </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">&#8212; Selecta to host conference call today at 8&#58;30 AM ET &#8212; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">WATERTOWN, Mass., November 3, 2022</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> -- </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Selecta Biosciences, Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> (NASDAQ&#58; SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR&#174; platform to develop tolerogenic therapies for autoimmune diseases, unlock the potential of gene therapies and amplify the efficacy of biologic therapies, today reported financial results for the third quarter ended September 30, 2022 and provided a business update.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;We are pleased with the steady progress seen across our clinical and pre-clinical pipelines.  With expected financial runway into mid-2024 we believe we are well-positioned to execute on our key priorities and achieve multiple near-term value driving inflection points,&#8221; said Carsten Brunn, Ph.D., president and chief executive officer of Selecta. &#8220;Clinically, we remain on track to initiate the Phase 1 trial of SEL-302, our wholly owned gene therapy in combination with ImmTOR for the treatment of MMA in Q4 2022, and expect to report joint topline data from the Phase 3 DISSOLVE clinical program investigating SEL-212 in chronic refractory gout, in Q1 2023.  Preclinically, with our external partners we continue to drive toward candidate selection for an IgA protease to treat IgA nephropathy, as well as progress IND-enabling studies and manufacturing scale-up for Xork, our proprietary IgG protease developed as a pre-treatment to enable AAV gene therapies.  Finally, building on the recently presented data at ESGCT, we continue our work in identifying a proprietary IL-2 to combine with ImmTOR, which we anticipate announcing by year-end. We believe ImmTOR- IL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, based on the synergistic effects we have observed preclinically, has the potential to be a generational leap forward for our precision immune tolerance platform.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Recent Program Highlights and Anticipated Upcoming Milestones&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tolerogenic Therapies for Autoimmune Disease&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%;padding-left:13.8pt;text-decoration:underline">ImmTOR-IL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Preclinically, Selecta has observed synergistic activity when ImmTOR is combined with engineered IL-2 molecules that are selective for Tregs (ImmTOR-IL&#8482;). </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Furthermore, when ImmTOR-IL was co-administered with an antigen of interest, the resulting data suggested that ImmTOR-IL may have profound synergistic effects in expanding antigen-specific Tregs when compared to ImmTOR alone, positioning ImmTOR-IL as a potential first-in-class antigen-specific therapy for the treatment of autoimmune disease.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.75pt">Selecta continues to work with its partners to develop a next generation IL-2 molecule to combine with ImmTOR and still anticipates </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">selecting an IL-2 candidate by year-end 2022.  </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.75pt">Selecta continues internal work on identifying additional target indications in autoimmune disease. Selecta plans to adopt a staged development approach, starting first with diseases driven by a single pathogenic antigen, such as Primary Biliary Cholangitis (PBC), then accelerating development across related indications.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-indent:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.15pt;text-decoration:underline">Primary biliary cholangitis (PBC)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#58; Selecta intends to co-administer ImmTOR-IL with PDC-E2, the autoantigen implicated in PBC and continues IND-enabling work for this combination.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Gene Therapies&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.15pt;text-decoration:underline">SEL-302 for MMA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#58; Selecta remains on track to initiate a Phase 1&#47;2 clinical trial of SEL-302, an AAV gene therapy combined with ImmTOR for the treatment of MMA, in the fourth quarter of 2022.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.15pt;text-decoration:underline">SEL-018 IgG Protease (Xork)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#58; In collaboration with Genovis, Selecta continues to advance Xork, a next-generation IgG protease, to help address disease in patients who are ineligible for gene therapies due to pre-existing anti-AAV antibodies.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Selecta believes </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">the novel combination of Xork and ImmTOR has the potential to address two of the key hurdles in gene therapy today&#58; pre-existing immunity to AAVs and the inability to re-dose AAV gene therapies due to the immune response to AAV capsids.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.11pt">IND-enabling studies and manufacturing scale-up activities are ongoing.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.15pt;text-decoration:underline">ImmTOR-IL&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In October 2022, we presented preclinical data at the 29th Annual European Society of Gene and Cell Therapy (ESGCT) Conference further supporting the potential therapeutic utility of ImmTOR in enabling safe repeated vector dosing and mitigating unwanted immune responses. Additionally, we presented data in which we observed the potential of ImmTOR-IL in driving antigen-specific Treg expansion while synergistically inhibiting formation of anti-AAV antibodies at high vector doses.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Biologic Therapies&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%;padding-left:13.8pt;text-decoration:underline">SEL-212 for chronic refractory gout</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#58; Selecta continues to advance DISSOLVE, the Phase 3 development program of SEL-212, which has been licensed to Sobi. </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">In Q3 2022, Selecta received a $10 million milestone payment from Sobi following the completion of enrollment of DISSOLVE II in June 2022.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">DISSOLVE I &#38; II trials are on track for completion in Q1 2023 with joint topline readout expected in Q1 2023.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%;padding-left:12.53pt;text-decoration:underline">ImmTOR with IgA protease for IgA nephropathy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Selecta continues to work with its partners to identify and develop a next generation IgA protease to combine with ImmTOR, and consistent with prior guidance anticipates selecting an enzyme candidate by year-end 2022. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Further Corporate and Partnership Updates&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">In Q3 2022, and as previously disclosed, Selecta received a $2 million payment from Sarepta relating to the extension of its Research License and Option Agreement for ImmTOR in Duchenne Muscular Dystrophy (DMD) and certain Limb-Girdle Muscular Dystrophies (LGMD) for an additional nine months to Q1 2023, and an additional $4 million payment from Sarepta for achievement of certain preclinical milestones.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Third Quarter 2022 Financial Results</font></div><div style="padding-left:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Cash Position&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> Selecta had $148.0 million in cash, cash equivalents, marketable securities, and restricted cash as of September 30, 2022, as compared to cash, cash equivalents, marketable securities, and restricted cash of $129.4 million as of December 31, 2021. Net cash used in operating activities was $19.8 million for the nine months ended September 30, 2022, as compared to $28.9 million of cash used in operating activities for the same period in 2021. Selecta believes its available cash, cash equivalents, restricted cash, and marketable securities will be sufficient to meet its operating requirements into mid-2024. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Collaboration and License Revenue&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Collaboration and license revenue for the third quarter of 2022 was $20.7 million, as compared to $24.4 million for the same period in 2021. Revenue was primarily driven by the shipment of clinical supply and the reimbursement of costs incurred for the Phase 3 DISSOLVE clinical program under the license agreement with Sobi.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Research and Development Expenses&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> Research and development expenses for the third quarter of 2022 were $16.5 million, as compared to $21.0 million for the same period in 2021. The decrease in cost was primarily the result of a decrease in expenses incurred for the SEL-212 clinical program, preclinical programs, and the AskBio collaboration.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">General and Administrative Expenses&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">General and administrative expenses for the third quarter of 2022 were $5.8 million, as compared to $5.4 million for the same period in 2021. The increase in costs was primarily the result of expenses incurred for stock compensation and personnel expenses.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Net Income (loss)&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the third quarter of 2022, Selecta reported net loss of $7.9 million, or basic net loss per share of $0.05, compared to net loss of $17.9 million, or basic net loss per share of $0.16, for the same period in 2021.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Conference Call and Webcast Reminder</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Selecta management will host a conference call at 8&#58;30 AM ET today to provide a business update and review the company&#8217;s third quarter 2022 financial results. Individuals may participate in the live call via telephone by dialing (844) 845-4170 (domestic) or +1 (412) 717-9621 (international) and may access a teleconference replay for one week by dialing (877) 344-7529 (domestic) or +1 (412) 317-0088 (international) and using confirmation code 10157874. Investors and the public can access the live and archived webcast of this call and a copy of the presentation via the Investors &#38; Media section of the company&#8217;s website, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">www.selectabio.com.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Selecta Biosciences, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Selecta Biosciences Inc. (NASDAQ&#58; SELB) is a clinical stage biotechnology company leveraging its ImmTOR&#174; platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body&#8217;s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">www.selectabio.com.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Selecta Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Any statements in this press release about the future expectations, plans and prospects of Selecta Biosciences, Inc. (the &#8220;Company&#8221;), including without limitation, statements regarding the Company&#8217;s cash runway, the unique proprietary technology platform of the Company, and the unique proprietary platform of its partners, the potential of ImmTOR to enable re-dosing of AAV gene therapy and to mitigate immunogenicity, the potential of ImmTOR and the Company&#8217;s product pipeline to treat chronic refractory gout, MMA, IgAN, other autoimmune diseases, lysosomal storage disorders, or any other disease, the anticipated timing or the outcome of ongoing and planned clinical trials, studies and data readouts, the anticipated timing or the outcome of the FDA&#8217;s review of the Company&#8217;s regulatory filings, the Company&#8217;s and its partners&#8217; ability to conduct its and their clinical trials and preclinical studies, the timing or making of any regulatory filings, the anticipated timing or outcome of selection of developmental product candidates, the potential treatment applications of product candidates utilizing the ImmTOR platform in areas such as gene therapy, gout and autoimmune disease, the ability of the Company and its partners where applicable to develop gene therapy products using ImmTOR, the novelty of treatment paradigms that the Company is able to develop, whether the observations made in non-human study subjects will translate to studies performed with human beings, the potential of any therapies developed by the Company to fulfill unmet medical needs, the Company&#8217;s plan to apply its ImmTOR technology platform to a range of biologics for rare and orphan genetic diseases, the potential of the Company&#8217;s technology to enable repeat administration in gene therapy product candidates and products, the ability to re-dose patients and the potential of ImmTOR to allow for re-dosing, the potential to safely re-dose AAV, the ability to restore transgene expression, the potential of the ImmTOR technology platform generally and the Company&#8217;s ability to grow its strategic partnerships and enrollment in the Company's clinical trials and other statements containing the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;hypothesize,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;would,&#8221; and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, the following&#58; the uncertainties inherent in the initiation, completion and cost of clinical trials including proof of concept trials, including the uncertain outcomes, the availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a particular clinical trial will be predictive of the final results of that trial and whether results of early clinical trials will be indicative of the results of later clinical trials, the ability to predict results of studies performed on human beings based on results of studies performed on non-human subjects, the unproven approach of the Company&#8217;s ImmTOR technology, potential delays in enrollment of patients, undesirable side effects of the Company&#8217;s product candidates, its reliance on third parties to manufacture its product candidates and to conduct its clinical trials, the Company&#8217;s inability to maintain its existing or future collaborations, licenses or </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">contractual relationships, its inability to protect its proprietary technology and intellectual property, potential delays in regulatory approvals, the availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements, the Company&#8217;s recurring losses from operations and negative cash flows, substantial fluctuation in the price of the Company&#8217;s common stock, risks related to geopolitical conflicts and pandemics and other important factors discussed in the &#8220;Risk Factors&#8221; section of the Company&#8217;s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in other filings that the Company makes with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent the Company&#8217;s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any intention to update any forward-looking statements included in this press release, except as required by law.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">For investors&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Bruce Mackle</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">LifeSci Advisors, LLC</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">+1-929-469-3859</font></div><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">bmackle&#64;lifesciadvisors.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">For media&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Brittany Leigh, Ph.D.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">LifeSci Communications, LLC</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">+1-813-767-7801</font></div><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">bleigh&#64;lifescicomms.com</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Tables</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selecta Biosciences, Inc. and Subsidiaries</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share data and par value)</font></div><div style="margin-bottom:3pt;text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.885%"><tr><td style="width:1.0%"></td><td style="width:68.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.757%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.758%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112,843&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114,057&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,599&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,998&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,925&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,914&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,310&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,474&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159,677&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144,443&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-current assets&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,904&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,142&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right-of-use asset, net </font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,056&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,829&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term restricted cash</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,600&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,379&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178,265&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159,883&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity</font></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">224&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,263&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,533&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loan payable</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,879&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,961&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease liability</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,552&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,049&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income taxes payable</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">601&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,820&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,883&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,728&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,251&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-current liabilities&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loan payable, net of current portion</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,215&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,673&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease liability, net of current portion</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,506&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,598&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,436&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,417&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrant liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,473&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,423&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total liabilities</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93,358&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137,362&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stockholders&#8217; equity&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock, $0.0001 par value&#59; 10,000,000 shares authorized&#59; no shares issued and outstanding as of September 30, 2022 and December 31, 2021</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $0.0001 par value&#59; 350,000,000 and 200,000,000 shares authorized as of September 30, 2022 and December 31, 2021, respectively&#59; 153,028,822 and 123,622,965 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">490,252&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">457,391&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(400,830)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(430,316)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,530)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,566)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84,907&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,521&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178,265&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159,883&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:3pt;text-align:center"><font><br></font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selecta Biosciences, Inc. and Subsidiaries</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Income (Loss)</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share data)</font></div><div style="margin-bottom:3pt;text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.885%"><tr><td style="width:1.0%"></td><td style="width:39.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.757%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.757%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.473%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration and license revenue</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,710&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,427&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93,982&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,140&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,539&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,951&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,410&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,418&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,770&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,445&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,538&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,397&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,309&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,396&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70,948&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63,815&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating income (loss)</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,599)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,969)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,034&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,675)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investment income</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">710&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">932&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency transaction, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(61)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(802)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(711)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,224)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,133)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of warrant liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,539)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">592&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,329&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,335)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income (loss) before income taxes</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,214)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,066)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,165&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22,098)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax (expense) benefit</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">321&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,828)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">321&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,828)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,893)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,894)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,486&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(37,926)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss)&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total comprehensive income (loss)</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,943)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,896)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,522&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(37,922)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss) per share&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.05)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.16)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.21&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.34)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</font></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.05)</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.16)</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.15&#160;</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.34)</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average common shares outstanding&#58;</font></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152,849,992&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115,169,949&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141,969,449&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113,161,622&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152,849,992&#160;</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115,169,949&#160;</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143,792,060&#160;</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113,161,622&#160;</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>selb-20221103.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:4896fb3f-ac14-41b0-9b6b-0207fb0b8dc2,g:e4027e9c-0c95-4fb1-84c4-695c0f8d790e-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:selb="http://www.selectabio.com/20221103" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.selectabio.com/20221103">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="selb-20221103_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="selb-20221103_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPageDocument" roleURI="http://www.selectabio.com/role/CoverPageDocument">
        <link:definition>0000001 - Document - Cover Page Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>selb-20221103_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:4896fb3f-ac14-41b0-9b6b-0207fb0b8dc2,g:e4027e9c-0c95-4fb1-84c4-695c0f8d790e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_PreCommencementTenderOffer_7c5ec8c9-1f89-43a2-ad54-0b604e65439c_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_801f3c3e-616d-4f24-acc4-9e94466844e5_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_83bc4ff9-22a5-44d1-a57c-9b7fd518570b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_face42c6-61bd-4062-8482-668a07fc59dc_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_f02585c5-075b-4570-ace2-0cb9c0e54139_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_532ba47b-a13b-4210-9f7a-2f48fabcf13e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_8ff10968-0d5d-40a3-b5d2-d27edb92d95b_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_f5df8552-966b-4e19-9a5f-4fc9472904fd_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_4d776055-4a0d-4de2-a3b0-52e883cc7bf7_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_3c6907db-b8df-4298-8c9c-655fdf64c7c1_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_64424fdc-acd7-4ffd-8994-be8242e840bd_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_a8a5ba4b-5827-49cd-bbfb-a6ef86951e35_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_32ab111f-8d2b-4f83-8cb0-a075ba44be70_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_f86d0daf-542f-4396-bde2-9b5c5356cae5_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_6f55b2fc-0f95-4bb0-b10e-03d085bbd1be_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_2842f5a0-fa34-4221-afc8-aa374574be07_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_08268299-3c1a-48cb-9b6a-75ca326dee5d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_abcaf27f-0d10-4965-802b-d04677550b0f_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_d0feffc0-1362-458b-ace7-c2b643de8eb0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_903c85c6-dba7-4b98-874f-546b5d280926_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_f4acd240-362b-4fcb-9435-66f69ad73794_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_bc1518a0-ada9-424d-b017-41ffafc4f0e6_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_0a750f98-48f9-44e1-a25c-ad0e058a3ac7_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>selb-20221103_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:4896fb3f-ac14-41b0-9b6b-0207fb0b8dc2,g:e4027e9c-0c95-4fb1-84c4-695c0f8d790e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.selectabio.com/role/CoverPageDocument" xlink:type="simple" xlink:href="selb-20221103.xsd#CoverPageDocument"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/CoverPageDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_40c00d8a-ac20-4c5e-8b96-b9a0afebd2c8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_c1213f34-0b43-4d51-a3bd-54380cfa5a10" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40c00d8a-ac20-4c5e-8b96-b9a0afebd2c8" xlink:to="loc_dei_DocumentType_c1213f34-0b43-4d51-a3bd-54380cfa5a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_a43f44fe-9d42-44c5-9637-4707d65ab418" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40c00d8a-ac20-4c5e-8b96-b9a0afebd2c8" xlink:to="loc_dei_DocumentPeriodEndDate_a43f44fe-9d42-44c5-9637-4707d65ab418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_7efbe98d-d853-406b-8736-c83ad2e320a3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40c00d8a-ac20-4c5e-8b96-b9a0afebd2c8" xlink:to="loc_dei_EntityRegistrantName_7efbe98d-d853-406b-8736-c83ad2e320a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_09588bf5-dbba-4210-a39a-1553dd0793b9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40c00d8a-ac20-4c5e-8b96-b9a0afebd2c8" xlink:to="loc_dei_EntityIncorporationStateCountryCode_09588bf5-dbba-4210-a39a-1553dd0793b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_d739bca3-ba5a-4c61-8126-f0158969a7b4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40c00d8a-ac20-4c5e-8b96-b9a0afebd2c8" xlink:to="loc_dei_EntityFileNumber_d739bca3-ba5a-4c61-8126-f0158969a7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_da501619-659f-4aa0-a8e0-209256bd1181" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40c00d8a-ac20-4c5e-8b96-b9a0afebd2c8" xlink:to="loc_dei_EntityTaxIdentificationNumber_da501619-659f-4aa0-a8e0-209256bd1181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d7a525a1-dd12-4aee-8cc7-c77d5607dc62" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40c00d8a-ac20-4c5e-8b96-b9a0afebd2c8" xlink:to="loc_dei_EntityAddressAddressLine1_d7a525a1-dd12-4aee-8cc7-c77d5607dc62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_d35f1caa-9010-49e9-99d2-0f8bbf75f261" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40c00d8a-ac20-4c5e-8b96-b9a0afebd2c8" xlink:to="loc_dei_EntityAddressCityOrTown_d35f1caa-9010-49e9-99d2-0f8bbf75f261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_9a50a01d-b4cd-4b1d-8c9f-eb9e18bfffa4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40c00d8a-ac20-4c5e-8b96-b9a0afebd2c8" xlink:to="loc_dei_EntityAddressStateOrProvince_9a50a01d-b4cd-4b1d-8c9f-eb9e18bfffa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_92ff8561-c879-41d2-b83e-3ba0ebb88b40" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40c00d8a-ac20-4c5e-8b96-b9a0afebd2c8" xlink:to="loc_dei_EntityAddressPostalZipCode_92ff8561-c879-41d2-b83e-3ba0ebb88b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_5329eaca-3043-4efc-9c2a-0a3028aef3ae" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40c00d8a-ac20-4c5e-8b96-b9a0afebd2c8" xlink:to="loc_dei_CityAreaCode_5329eaca-3043-4efc-9c2a-0a3028aef3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_dba8e6b7-123d-4840-8e95-0e83fd2a158d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40c00d8a-ac20-4c5e-8b96-b9a0afebd2c8" xlink:to="loc_dei_LocalPhoneNumber_dba8e6b7-123d-4840-8e95-0e83fd2a158d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_b39cd971-d482-4af6-b7d5-f5e842e9d393" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40c00d8a-ac20-4c5e-8b96-b9a0afebd2c8" xlink:to="loc_dei_WrittenCommunications_b39cd971-d482-4af6-b7d5-f5e842e9d393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_7781b255-70e0-4f5d-b9d6-50dd77856681" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40c00d8a-ac20-4c5e-8b96-b9a0afebd2c8" xlink:to="loc_dei_SolicitingMaterial_7781b255-70e0-4f5d-b9d6-50dd77856681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_066e28b6-8bbb-40b7-97d3-93c8628e6eb6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40c00d8a-ac20-4c5e-8b96-b9a0afebd2c8" xlink:to="loc_dei_PreCommencementTenderOffer_066e28b6-8bbb-40b7-97d3-93c8628e6eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_529767af-c1f3-4b05-a2a9-e49680436269" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40c00d8a-ac20-4c5e-8b96-b9a0afebd2c8" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_529767af-c1f3-4b05-a2a9-e49680436269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_997bfe5f-7190-4b7c-91ef-c3fcb2453226" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40c00d8a-ac20-4c5e-8b96-b9a0afebd2c8" xlink:to="loc_dei_Security12bTitle_997bfe5f-7190-4b7c-91ef-c3fcb2453226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_841717d3-4da5-4654-a5da-2c36c10fd49a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40c00d8a-ac20-4c5e-8b96-b9a0afebd2c8" xlink:to="loc_dei_TradingSymbol_841717d3-4da5-4654-a5da-2c36c10fd49a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_86da0988-bae7-49a3-b923-d370589f1373" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40c00d8a-ac20-4c5e-8b96-b9a0afebd2c8" xlink:to="loc_dei_SecurityExchangeName_86da0988-bae7-49a3-b923-d370589f1373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_9273e2ef-19be-44cf-b81a-2fba4f3e5e2c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40c00d8a-ac20-4c5e-8b96-b9a0afebd2c8" xlink:to="loc_dei_EntityEmergingGrowthCompany_9273e2ef-19be-44cf-b81a-2fba4f3e5e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_370333c1-c3c1-4a68-888f-3c53029da88e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40c00d8a-ac20-4c5e-8b96-b9a0afebd2c8" xlink:to="loc_dei_EntityCentralIndexKey_370333c1-c3c1-4a68-888f-3c53029da88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e644503c-c04e-4cbb-8284-058f44618998" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40c00d8a-ac20-4c5e-8b96-b9a0afebd2c8" xlink:to="loc_dei_AmendmentFlag_e644503c-c04e-4cbb-8284-058f44618998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>selectalogoa06.jpg
<TEXT>
begin 644 selectalogoa06.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#T17AI9@  34T *@    @ ! $[  (
M   .   (2H=I  0    !   (6)R=  $    <   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $QA=7)I92!'
M;&%V:6X   60 P "    %   $*:0!  "    %   $+J2D0 "     S4S  "2
MD@ "     S4S  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH \Q^,=TZ+I, 8B-C*Y&>"1M _+)_.N^T+3;?2-$M;.T50B1C+
M??;'+'W)KEOBGX;NM<T"*[TY&EN=/+/Y2]71@-V!W(V@X^O?%8'@GXLZ?!I<
M.G>)9'A>W4)'=+&65D X# 9.>V<<]Z[+.=!*/0\12A0Q\Y5=.9*S/4KNTAOK
M.6UNHQ)#,I1U/<&O*?AA/)9>-K_35D,L1B=6*?=8HX ;Z<G'^]6GXG^,&D6^
MFR1>')7N[R1<),8BB19[_, 21V&,?RIGPA\-W%G:SZY?Q-$UT@CME;@F/(8M
MCT)"X^A/0BB"=.E+GZBK2AB,92]B[N-[M=OZ_,],HHHKC/<$9E12SD*JC)).
M !7F?B35I/%FKP66DP-+'$2(SC#2$]6.>@X[_CZ#8\?:VT42:1:D^9, TQ7^
M[GA?Q(S],>M;'A7P]'HFFJTB?Z9,H,S'!*_[ ]A^I_"N"JW7G[&.RW_R/:PR
MC@Z2Q4U>3^%?K_7ZE+1/ EC8*LNI;;RXZ[2/W:GZ=_Q_*NHBBC@C6.%%C11A
M508 _"G45UTZ4*:M%'F5L15KRYJDKA5>\T^TU"/9>VT4ZX(&]02,^A[?A5BB
MK:35F8QDXN\79G :YX'FLG-]X?>1MC;Q"#\Z=_D/4X].OUK%\.VB^(/$T::O
M<R2?*7/F.2TNW^')_P X!KUFN!\;Z$UE<)KFG#R_G!FV#&U\\/\ B>OOCUKS
M,1AHT_WD5HMT?0X+'SK)T*CM)JREU.\1%CC5(U5$4 *JC  '8"G5F>']6&M:
M+#=D*LARLJKT5AU_/@_C6G7I1DI14EL>!4A*G-PEN@HHHJB HHHH \-\&:<O
MQ(^(VI:]K$:R65NPD-N_(.<B)".X 7GUV\]37N$<:11K'$JHB *JJ,!0.@ K
MPSPMJA^%GC[4=(UL.+"Y(7S]G.T$F.7 SD88@@="?48KW&"XANK=)[65)H9!
MN22-@RL/4$=:Z<1?F7;H>7EO+R-/X[N_<DJ.XMH+NW>"[ACGAD&'CE0,K#T(
M/!J2BN8]3<XW3/ACHNC^,8]?TQY[?R@VRT4@QAF4J3D\XP3QZ^W%=E1152E*
M6YG3I0I)J"L%%0WEY;Z?9R75[,D%O$NYY)&PJCZUY9KOQNC6<VWA;3C=-NVK
M/<@A6.>R#D@^Y!]JJ%.4_A1G6Q-*@OWC/6:*\7G^*?CNQA%QJ'AJ&"WR,O)9
M3H"/]XMBNM\)_%?1O$EU'97,;:;?2':D<KAD<]@K\<^Q ]!FJE0G%7,:>/H3
MERWL_,[NN<^(7_)/=9_Z]C_,5T=<Y\0O^2>ZS_U['^8J*?QHWQ'\&?H_R.9^
M!O\ R(]Y_P!A%_\ T7'7I->;? W_ )$>\_["+_\ HN.O2:JM_$9E@?\ =H>@
M45RWBWX@Z-X1'E7;M<7K#*VL&"PXX+'HHZ>_/ -<!%\7/&&K3R-H/AR&>!3P
MJ6\T[+]64@?H*<:,Y*Z"KC:%*7*W=^6I[117CNG_ !KU&ROFMO%>AB+!^;[.
MK1O&/=')S^8KU+1-=T[Q%I:7^DW"SP,<'LR-W5AU!_\ U]#4SI3ANBJ.+HU]
M(/7L:%%%(S*B%W8*JC)). !69U"T5YMXD^-&DZ7-);:+;MJ<R$J9=^R$'U!Y
M+<^@ /8UAQ?$OXAW$ GM_"T<D)&1(FGW#*1]0U;JA-JYP2S##QERIW]-3V6B
MO*-"^-T#S+;>*-.:SDSM:>W!95.>Z'Y@![%C[5Z+<ZIYWAFXU30]E^WV5YK4
M)EA*P4E5XYY(QCK42IR@[-&U+%4JT6X.]OO.:^+_ /R3>]_ZZQ?^ABIOA/\
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MI#+<*V]$)*Y5RI(SV.W..V>IZUDX24>9G5'$4YU/9Q=W:_R-NBBBH-PHHHH
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MTH1VMI]Z.PHHHKC/;"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY(&164*,Y/561U5L=1IQO%\SZ):GLFEZM8:U9"[TJZCNH-Q7?&<X(Z@^A_\
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M/_(GZA_US'_H0K6C_$CZHY,;_NM3_"_R.+\'^#]/\0:/+=WLURCK.8P(F4#
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M.,))QV:N:97B*E>E)57=Q;5^]@HHHKF/5"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH \D^%]G<P>/M6\Z"1/)@DCDW+]UC(N ?<[3^5>MT45C1I
M>RARWN=^/QCQM;VK5M$ON"BBBMC@"BBB@ HHHH *Q_%D,D_A/4(X4+N8LA5'
M)P03^@K8HJH2Y9*78RK4_:TI4WU37WGD/A_Q;?\ A[3WM+>SCE1Y3)F0-D$@
M#M]*U/\ A96J_P#0-@_)O\:]*HKLEB:4G=T_Q/$IY7BZ4%"&):2_N_\ !/,V
M\3^+?$"^1IEH8%8X+V\9'7L78X7Z\5O^$?!@T5A?:@5EOB/E Y6('KSW/O\
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/ 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140003255864160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page Document<br></strong></div></th>
<th class="th"><div>Nov. 03, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  03,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SELECTA BIOSCIENCES,&#160;INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-1622110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">65 Grove Street,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Watertown,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">923-1400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock (Par Value $0.0001)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SELB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001453687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>selb-20221103_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="selb-20221103.xsd" xlink:type="simple"/>
    <context id="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
        </entity>
        <period>
            <startDate>2022-11-03</startDate>
            <endDate>2022-11-03</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl80L2ZyYWc6MDkxOTVkYzg0YjFlNGE3Y2E3M2JjMmI2ZjU1MTAzMTMvdGFibGU6MGUyMTkwOTU0YzBiNDhhZDg0ZmM0Y2VhMDY1ODMxNzUvdGFibGVyYW5nZTowZTIxOTA5NTRjMGI0OGFkODRmYzRjZWEwNjU4MzE3NV8wLTEtMS0xLTY0NTYx_9c8a344e-d9c3-4ce3-9453-bf1873bfe094">0001453687</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl80L2ZyYWc6MDkxOTVkYzg0YjFlNGE3Y2E3M2JjMmI2ZjU1MTAzMTMvdGFibGU6MGUyMTkwOTU0YzBiNDhhZDg0ZmM0Y2VhMDY1ODMxNzUvdGFibGVyYW5nZTowZTIxOTA5NTRjMGI0OGFkODRmYzRjZWEwNjU4MzE3NV8xLTEtMS0xLTY0NTYx_9a37ee6f-c57e-4b01-ba31-4a8d5d625aea">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGV4dHJlZ2lvbjpkNTA4ZWZmYWMzZjc0YzQ4YTRhMmUwMGQ4ZWQyZmU0Zl8xMjcx_f4528ed7-e0c7-4d5a-b074-0cac8386263d">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGV4dHJlZ2lvbjpkNTA4ZWZmYWMzZjc0YzQ4YTRhMmUwMGQ4ZWQyZmU0Zl8yMzQ_375009c3-57ff-4eec-96d6-be4bd2a8fd75">2022-11-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGV4dHJlZ2lvbjpkNTA4ZWZmYWMzZjc0YzQ4YTRhMmUwMGQ4ZWQyZmU0Zl8xMjY0_028fdc0b-06fc-47ad-b3aa-2c881284d146">SELECTA BIOSCIENCES,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGFibGU6ZWMxZWRmNmRkZDZhNGJkNmFmMzRhZjkxMzYzNWFhYjMvdGFibGVyYW5nZTplYzFlZGY2ZGRkNmE0YmQ2YWYzNGFmOTEzNjM1YWFiM18wLTAtMS0xLTY0NTYx_0aecd294-e04e-40a4-99e4-7c44601a6da3">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGFibGU6ZWMxZWRmNmRkZDZhNGJkNmFmMzRhZjkxMzYzNWFhYjMvdGFibGVyYW5nZTplYzFlZGY2ZGRkNmE0YmQ2YWYzNGFmOTEzNjM1YWFiM18wLTItMS0xLTY0NTYx_3811281f-ab82-4c71-a151-89b735d47add">001-37798</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGFibGU6ZWMxZWRmNmRkZDZhNGJkNmFmMzRhZjkxMzYzNWFhYjMvdGFibGVyYW5nZTplYzFlZGY2ZGRkNmE0YmQ2YWYzNGFmOTEzNjM1YWFiM18wLTQtMS0xLTY0NTYx_44195484-e640-4b02-90fb-41e04e68bdd2">26-1622110</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGV4dHJlZ2lvbjpkNTA4ZWZmYWMzZjc0YzQ4YTRhMmUwMGQ4ZWQyZmU0Zl8xMjcy_35ef3eef-e2ec-425f-8b63-cb2100338d18">65 Grove Street,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGV4dHJlZ2lvbjpkNTA4ZWZmYWMzZjc0YzQ4YTRhMmUwMGQ4ZWQyZmU0Zl8xMjcz_992f4329-ffe5-40eb-ba57-fd1bdceae609">Watertown,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGV4dHJlZ2lvbjpkNTA4ZWZmYWMzZjc0YzQ4YTRhMmUwMGQ4ZWQyZmU0Zl8xMjY2_896c4a5b-a4bf-4a5e-900f-1846236fd4f0">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGV4dHJlZ2lvbjpkNTA4ZWZmYWMzZjc0YzQ4YTRhMmUwMGQ4ZWQyZmU0Zl8xMjY1_8a825411-1d3e-4e30-a930-c08ab8bbda74">02472</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGV4dHJlZ2lvbjpkNTA4ZWZmYWMzZjc0YzQ4YTRhMmUwMGQ4ZWQyZmU0Zl8xMjY3_9a97d05c-1e42-4328-9f0b-5f16566c2580">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGV4dHJlZ2lvbjpkNTA4ZWZmYWMzZjc0YzQ4YTRhMmUwMGQ4ZWQyZmU0Zl8xMjY4_e53392cd-4165-4249-811f-b7e93a8024a3">923-1400</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGFibGU6NWRkMjgyNDIzNGYxNGZhYzg4NjFiMjgwMmYzYTM0MmYvdGFibGVyYW5nZTo1ZGQyODI0MjM0ZjE0ZmFjODg2MWIyODAyZjNhMzQyZl8wLTAtMS0xLTY0NTYx_c7191237-cbbb-4051-8bd6-6bf293c0d886">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGFibGU6NWRkMjgyNDIzNGYxNGZhYzg4NjFiMjgwMmYzYTM0MmYvdGFibGVyYW5nZTo1ZGQyODI0MjM0ZjE0ZmFjODg2MWIyODAyZjNhMzQyZl8yLTAtMS0xLTY0NTYx_9956eab2-491e-45ec-8c0e-9ba02818e14e">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGFibGU6NWRkMjgyNDIzNGYxNGZhYzg4NjFiMjgwMmYzYTM0MmYvdGFibGVyYW5nZTo1ZGQyODI0MjM0ZjE0ZmFjODg2MWIyODAyZjNhMzQyZl80LTAtMS0xLTY0NTYx_c08b8ce5-ca44-4273-bb6a-1c41fe20f44c">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGFibGU6NWRkMjgyNDIzNGYxNGZhYzg4NjFiMjgwMmYzYTM0MmYvdGFibGVyYW5nZTo1ZGQyODI0MjM0ZjE0ZmFjODg2MWIyODAyZjNhMzQyZl82LTAtMS0xLTY0NTYx_7f96fa20-4517-4720-932a-6741ee7ef8c4">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGFibGU6M2Q5MjdiODI4ZGM3NDE1NWJhZjRkNzJkZWE0ZWVmYjQvdGFibGVyYW5nZTozZDkyN2I4MjhkYzc0MTU1YmFmNGQ3MmRlYTRlZWZiNF8zLTAtMS0xLTY0NTYx_144930e1-78ba-435a-bdc1-cf26cad7643e">Common Stock (Par Value $0.0001)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGFibGU6M2Q5MjdiODI4ZGM3NDE1NWJhZjRkNzJkZWE0ZWVmYjQvdGFibGVyYW5nZTozZDkyN2I4MjhkYzc0MTU1YmFmNGQ3MmRlYTRlZWZiNF8zLTEtMS0xLTY0NTYx_bba0c4dd-c2bf-4e79-a61a-0d8220625d07">SELB</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGFibGU6M2Q5MjdiODI4ZGM3NDE1NWJhZjRkNzJkZWE0ZWVmYjQvdGFibGVyYW5nZTozZDkyN2I4MjhkYzc0MTU1YmFmNGQ3MmRlYTRlZWZiNF8zLTItMS0xLTY0NTYx_ede2d859-5747-474e-bb8b-f0466dfd8136">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTJkNzllMjgyMzQyYzhhOWQ5Y2M3ODUwZGZjMGViL3NlYzoyNmEyZDc5ZTI4MjM0MmM4YTlkOWNjNzg1MGRmYzBlYl8xL2ZyYWc6ZDUwOGVmZmFjM2Y3NGM0OGE0YTJlMDBkOGVkMmZlNGYvdGV4dHJlZ2lvbjpkNTA4ZWZmYWMzZjc0YzQ4YTRhMmUwMGQ4ZWQyZmU0Zl8xMjY5_985c8629-68bc-45d4-a613-e0881b520a2d">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M><U/UYR!4=@7X/E2*7.XL#O8XA\0@_\ 4$L#!!0    (  I 8U6?H!OPL0(
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M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
M"D!C5;9@N9SM    *P(  !$              ( !KP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ "D!C59E<G",0!@  G"<  !,
M ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  *0&-5,7_"
M+U$$  ",$   &               @($,"   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ "D!C59^@&_"Q @  X@P   T
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;72YX;6Q02P4&      D "0 ^ @  [1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="selb-20221103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/CoverPageDocument</Role>
      <ShortName>Cover Page Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="selb-20221103.htm">selb-20221103.htm</File>
    <File>exhibit991_earningsrelease.htm</File>
    <File>selb-20221103.xsd</File>
    <File>selb-20221103_lab.xml</File>
    <File>selb-20221103_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "selb-20221103.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "selb-20221103.htm"
     ]
    },
    "labelLink": {
     "local": [
      "selb-20221103_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "selb-20221103_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "selb-20221103.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "selb",
   "nsuri": "http://www.selectabio.com/20221103",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20221103.htm",
      "contextRef": "ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page Document",
     "role": "http://www.selectabio.com/role/CoverPageDocument",
     "shortName": "Cover Page Document",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20221103.htm",
      "contextRef": "ib738bc8940cf44e28a96da927c2cd9be_D20221103-20221103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001453687-22-000136-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001453687-22-000136-xbrl.zip
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M=3IO;,ADV$V@Z!RWRW^1U4"[K\K.-@-8?_M_R59_I.&ES@"E?0BHZC>MIMW
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MQ,X)*=F6=L'1H&XJO3/B%F1S^?=C8!>1 5"#* ]3J91TX2MM$4C;ZRXG9Y_
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MFSUZ[8;$N\WXF3YZ^V+S2;YZ]_C;%_\'4$L#!!0    (  I 8U767@>PL 8
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M87)N:6YG<W)E;&5A<V4N:'1M4$L! A0#%     @ "D!C5<6A1MBO%   =)D
M !$              ( !BR<  '-E;&(M,C R,C$Q,#,N:'1M4$L! A0#%
M  @ "D!C57]924=T @  F@<  !$              ( !:3P  '-E;&(M,C R
M,C$Q,#,N>'-D4$L! A0#%     @ "D!C58=<=BJ "@  25X  !4
M     ( !##\  '-E;&(M,C R,C$Q,#-?;&%B+GAM;%!+ 0(4 Q0    (  I
M8U767@>PL 8   0Q   5              "  ;])  !S96QB+3(P,C(Q,3 S
>7W!R92YX;6Q02P4&      4 !0!0 0  HE

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
